Fisher Funds Management LTD Has $57.19 Million Stock Holdings in DexCom, Inc. $DXCM

Fisher Funds Management LTD trimmed its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 25.3% in the first quarter, HoldingsChannel.com reports. The fund owned 910,584 shares of the medical device company’s stock after selling 308,264 shares during the quarter. DexCom comprises about 1.7% of Fisher Funds Management LTD’s investment portfolio, making the stock its 14th biggest position. Fisher Funds Management LTD’s holdings in DexCom were worth $57,185,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Trust Co. of Vermont increased its position in shares of DexCom by 14.8% in the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock worth $74,000 after purchasing an additional 145 shares during the period. CVA Family Office LLC lifted its position in DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares during the period. IFP Advisors Inc lifted its position in DexCom by 24.7% during the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after purchasing an additional 178 shares during the period. Personal CFO Solutions LLC grew its stake in DexCom by 5.0% during the third quarter. Personal CFO Solutions LLC now owns 3,864 shares of the medical device company’s stock worth $260,000 after buying an additional 185 shares in the last quarter. Finally, Keel Point LLC grew its stake in DexCom by 3.1% during the fourth quarter. Keel Point LLC now owns 6,473 shares of the medical device company’s stock worth $430,000 after buying an additional 193 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Stifel Nicolaus set a $90.00 target price on shares of DexCom and gave the company a “buy” rating in a report on Friday, June 5th. Citigroup reaffirmed a “buy” rating and set a $84.00 price target (up from $79.00) on shares of DexCom in a report on Thursday, May 28th. Benchmark initiated coverage on shares of DexCom in a research report on Monday, May 11th. They set a “buy” rating and a $77.00 price target on the stock. BTIG Research reissued a “buy” rating and issued a $85.00 price objective on shares of DexCom in a research note on Monday, March 9th. Finally, UBS Group set a $95.00 price objective on shares of DexCom in a research report on Wednesday, June 10th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average price target of $84.83.

Insider Activity at DexCom

In related news, insider Kevin R. Sayer sold 26,759 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total value of $1,926,648.00. Following the completion of the transaction, the insider owned 382,482 shares in the company, valued at $27,538,704. This trade represents a 6.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total transaction of $60,730.12. Following the sale, the director owned 25,007 shares in the company, valued at approximately $1,500,670.07. This represents a 3.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 46,694 shares of company stock valued at $3,343,977. Corporate insiders own 0.28% of the company’s stock.

DexCom Stock Performance

NASDAQ DXCM opened at $72.47 on Monday. The company has a market cap of $27.96 billion, a price-to-earnings ratio of 30.97, a price-to-earnings-growth ratio of 1.13 and a beta of 1.45. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The business’s fifty day moving average is $67.07 and its 200 day moving average is $67.95.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The business’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.32 EPS. As a group, sell-side analysts expect that DexCom, Inc. will post 2.58 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.